Weil Company’s AstraZeneca AZN Stock Holding History

Weil Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$206K	Buy	+1,045	New	+$201K	0.05%	115

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Weil Company's AZN Position: Q1 2026 in Review

Weil Company opened a new position in AstraZeneca (AZN) in Q1 2026: 1,045 shares worth $206K. The stake represents 0.05% of the portfolio and ranks #115 among its holdings.

1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Weil Company held 1,045 shares of AstraZeneca worth $206K as of Q1 2026.
AstraZeneca was a new Weil Company position in Q1 2026.
AstraZeneca made up 0.05% of Weil Company's portfolio in Q1 2026, its #115 holding.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Weil Company's 13F filing for Q1 2026, filed 15 Apr 2026.